Our top pick for
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NuGenerex, a subsidiary of Generex that focuses on immunotherapy cancer treatments, has plans to go public soon. Here's what we know — and how to buy in when it launches.
NuGenerex filed a draft registration with the US Securities and Exchange Commission under the ticker symbol NGIOP. Not yet an official IPO, it's one of the first steps of taking a private company public.
The stock is expected to cost $25. No date has been set for when the stock will be publicly available. The shares will be available on the Nasdaq Capital Market.
Once NuGenerex goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. But evaluating the performance of companies like NuGenerex can be useful in determining how the market is performing and whether now is a good time to invest in this industry. Select a company to learn more about what they do and how their stock performs, including market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield. While this list includes a selection of the most well-known and popular stocks, it doesn't include every stock available.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Zynga stock soared 49% on Take-Two acquisition news. Read on for more information.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
The SPAC merging with Trump’s media company saw 20% gain in one trading day.
Rivian’s share nears all-time lows after Amazon seals deal with a rival.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.